05, so the trial was not technically statistically significant, although if we added a few worsening heart failure events that needed emergency treatment but didn’t lead to hospital admission, that made the overall treatment effect significant, so it was borderline. The PARAGON-HF trial overall showed a borderline effect with sacubitril/valsartan on the primary composite outcome of cardiovascular death and heart failure hospitalizations. John McMurray, MBChB: The most recent attempt to identify treatments for patients with heart failure and preserved ejection fraction was with sacubitril/valsartan and the PARAGON-HF trial, which was the sister trial to PARADIGM-HF, which was the heart failure in reduced ejection fractions, sacubitril/valsartan trial.
0 kommentar(er)
